Second demand front open and funded: a different kind of buyer is now paying, and management is resourcing it while it i
The model's full reasoning — Q3 2023 call → NO我们根据提供的电话会议记录来判断。问题问的是：管理层是否描述公司除了历史主营业务之外，现在有第二个不同的需求来源，并且已经支付真金白银，同时管理层正在积极投入资源支持这个第二战线，而它仍然是公司较小的一部分。 我们需要检查三个条件： (1) 第二战线，种类不同：管理层识别出与历史主营不同的需求来源，比如不同类型的客户、行业、市场、地理、应用、用途或渠道。 (2) 已经在付费，不是预期：描述为当前正在产生实际业务，有实际收入、订单、合同、发货、客户、数量或付费使用。 (3) 仍然较小，并且正在投入资源：管理层表示这个第二战线仍然是公司明显较小的部分，并且描述了当前正在投入的实际努力或资源。 从记录中看，公司的主营业务是什么？从财务数据看，主要收入来自ProSense系统及一次性探针销售，以及之前与Terumo的独家分销权协议（但已结束）。历史主营业务似乎是销售ProSense设备用于多种适应症（如肿瘤、泌尿等），但重点可能是乳腺癌冷冻消融。 在电话会议中，管理层提到了多个市场：美国、欧洲、巴西、中国、印度等。但问题问的是“第二战线”是否与历史主营不同。历史主营可能是美国市场的某些适应症？或者可能是乳腺癌？但公司一直在推广ProSense用于多种适应症。 仔细阅读：管理层提到“在印度，首次使用ProSense进行了乳腺癌冷冻消融手术”，这可能是新市场。但印度是地理上的新市场，但仍然是同样的产品、同样的应用（乳腺癌）。这算“不同种类”吗？可能算地理上的新市场，但问题要求“不同种类的客户、行业、市场、地理、应用、用途或渠道”。地理是其中之一，所以印度作为新地理可能算。 但更重要的是，管理层是否明确将其描述为“第二战线”？他们提到“在印度，首次...”，但并没有强调这是一个与历史主营不同的新战线。他们提到“我们相信随着印度采用早期检测，转向微创解决方案将改善女性生活”，这似乎是市场拓展。 另外，管理层提到“在巴西，我们获得了批准，并开始商业活动”，以及“加拿大”等。这些可能是新市场。 但问题要求“第二战线”是“不同种类的需求来源”，而不仅仅是更多同样的买家。这里可能指的是不同的应用？例如，除了乳腺癌，还有肾脏、子宫内膜异位症等。管理层提到“17项额外的独立非赞助研究正在进行，用于ProSense”，包括肾脏、肺、肌肉骨骼等。但这是研究，不是付费业务。 关键点：是否有第二个不同的需求来源已经付费？管理层提到“ProSense系统和一次性探针销售增加了11%”，但这是整体销售，没有区分不同战线。 在电话会议中，管理层提到“在印度，首次进行了乳腺癌冷冻消融手术”，这可能是新市场，但这是否是“已经付费”的？他们提到“首次手术”，可能意味着有销售，但具体金额未提及。另外，他们提到“在巴西，我们获得了批准，并开始商业活动”，但也没有具体数字。 更重要的是，管理层是否明确将某个市场或应用视为“第二战线”并投入资源？他们提到“我们最近任命了Shad Good作为北美销售副总裁”，这是针对美国市场的，但美国是历史主营吗？可能美国是主要市场，但美国市场已经存在。 再看财务：总收入下降，因为Terumo协议结束，但产品销售额增加。所以产品销售额是主要业务。 问题问的是“第二战线”是否与历史主营不同。历史主营可能是美国市场的某些适应症？但公司一直在全球销售。 也许“第二战线”指的是除了乳腺癌之外的适应症？但管理层没有明确说。 在电话会议中，管理层提到“在印度，首次进行了乳腺癌冷冻消融手术”，这可能是新地理，但仍然是乳腺癌。另外，他们提到“在巴西，我们获得了批准”，也是新地理。 但问题要求“第二战线”是“不同种类的需求来源”，比如不同的客户类型（例如，从医院到诊所？）或不同的应用（例如，从乳腺癌到肾脏？）。管理层提到“独立研究”包括肾脏、子宫内膜异位症等，但那是研究，不是付费业务。 管理层提到“在CIRSE会议上，进行了肿瘤消融实操培训”，但那是培训。 我认为，管理层没有明确描述一个“第二战线”是已经付费且与历史主营不同的。他们主要是在全球扩展销售，但都是同样的产品、同样的适应症（乳腺癌等）。虽然地理不同，但可能不算“不同种类”，因为仍然是同样的产品卖给同样的医生。 另外，管理层提到“在印度，首次进行了乳腺癌冷冻消融手术”，这可能是新市场，但并没有说这是“第二战线”或投入资源。他们提到“我们相信印度将采用早期检测”，但那是未来。 关于资源投入，他们提到“我们最近任命了Shad Good作为北美销售副总裁”，但北美是历史主营吗？可能美国是主要市场，所以这不算第二战线。 也许“第二战线”指的是除了乳腺癌之外的适应症，比如肾脏？但管理层没有说这些适应症已经产生收入。 在财务部分，他们提到“ProSense系统和一次性探针销售增加了11%”，但没有细分。 因此，我认为没有明确证据表明存在一个“第二战线”已经付费且与历史主营不同，并且管理层正在投入资源。他们只是在全球扩展，但那是同一业务。 所以答案应该是NO。 但让我们再仔细看：管理层提到“在印度，首次进行了乳腺癌冷冻消融手术”，这可能是新市场，但仍然是乳腺癌。另外，他们提到“在巴西，我们获得了批准”，也是新市场。这些可能算作地理上的新战线，但问题要求“不同种类的需求来源”，地理是其中之一，但需要是“不同种类”的，比如不同客户类型或应用。这里可能只是新地理，但仍然是同样的客户（医生）和同样的应用（乳腺癌）。所以可能不算。 另外，管理层提到“在CIRSE会议上，进行了肿瘤消融实操培训”，但那是培训，不是销售。 我认为没有满足条件。 因此，答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| TNET | TriNet Group, Inc. | Q1 2024 | 2024-04-26 | C |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| OUT | Outfront Media Inc. | Q4 2023 | 2024-02-21 | C+ |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| CPRT | Copart, Inc. | Q1 2024 | 2023-11-16 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| RVLV | Revolve Group, Inc. | Q3 2023 | 2023-11-01 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| AYI | Acuity Brands, Inc. | Q2 2023 | 2023-04-04 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| ORGO | Organogenesis Holdings Inc. | Q4 2022 | 2023-03-01 | C |
| TWLO | Twilio Inc. | Q4 2022 | 2023-02-15 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| ADM | Archer-Daniels-Midland Company | Q4 2022 | 2023-01-26 | C+ |
| WGO | Winnebago Industries, Inc. | Q1 2023 | 2022-12-16 | D |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CMLS | Cumulus Media Inc. | Q3 2022 | 2022-10-28 | D |
| PKX | POSCO Holdings Inc. | Q3 2022 | 2022-10-24 | D |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| HLNE | Hamilton Lane Incorporated | Q1 2023 | 2022-08-02 | C+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| AKAM | Akamai Technologies, Inc. | Q4 2021 | 2022-02-15 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| UAA | Under Armour, Inc. | Q3 2017 | 2017-10-31 | F |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SBFG | SB Financial Group, Inc. | Q3 2017 | 2017-10-20 | A |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| EPC | Edgewell Personal Care Company | Q3 2017 | 2017-08-08 | D |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| TPB | Turning Point Brands, Inc. | Q1 2017 | 2017-05-11 | B |
| KHC | The Kraft Heinz Company | Q1 2017 | 2017-05-03 | F |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| MDLZ | Mondelez International, Inc. | Q4 2016 | 2017-02-07 | C |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
| AEHR | Aehr Test Systems | Q2 2017 | 2017-01-05 | F |
| LEE | Lee Enterprises, Incorporated | Q4 2016 | 2016-12-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| DUK | Duke Energy Corporation | Q2 2016 | 2016-08-04 | B |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| INGR | Ingredion Incorporated | Q1 2016 | 2016-05-01 | B+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| ALE | ALLETE, Inc. | Q4 2015 | 2016-02-18 | B |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
FFWM · Q3 2021 → YESThe question is: Does management describe a SECOND, DIFFERENT FRONT OF DEMAND that is ALREADY PAYING IT REAL MONEY, and are they ACTIVELY PUTTING RESOURCES BEHIND that second front while it's still sm...YES The transcript shows management describing a second front in Texas (and soon Florida) that is genuinely different in kind from the historical California-Nevada-Hawaii focus. They explicitly frame it as expansion into new geographies with new customers and channels, not more of the same. Texas is already generating real revenue: the L PO group "started to put numbers on the board last quarter" with $100-150 million annual run rate expected in Q1, and builder finance is "officially up and running and beginning to bring in new business" with first loans funded. Equipment finance and C&I (43% of originations) are also contributing to the shift. Management is actively feeding it with resources: recruiting, opening offices in Irving and Plano, staffing up, and treating it as core to the transformation.
T · Q3 2018 → YESThe question is: Does management describe that the company now has a SECOND, DIFFERENT FRONT OF DEMAND that is ALREADY PAYING IT REAL MONEY, and is management ACTIVELY PUTTING RESOURCES BEHIND that se...NO The transcript does not meet the criteria for a clear second front. WarnerMedia is an acquisition just consolidated, which is explicitly excluded. Xandr is described as a new advertising platform launched in the quarter, with revenues up more than 30% partly due to the AppNexus acquisition, but it is tied to 7 billion in consolidated annual ad revenues and is not framed as a distinct, different front from the historical business. The advertising activity, while growing, is presented as an expansion of existing capabilities rather than a genuinely new source of demand. Management is actively investing in it, but it does not satisfy the requirement of being a clearly smaller, different front already paying real money in a distinct way.
AEHR · Q2 2017 → YESThe question is about whether management describes a second, different front of demand that's already paying real money, and they're actively putting resources behind it while it's still smaller. NO The transcript describes the FOX-XP system as a new, exciting market for optical devices, photonics, sensors, and automotive ICs, with initial shipments in engineering configuration and expectations for production shipments in Q3. However, it does not clearly establish that this second front is already generating real current revenue or paying 100% of the conditions: the production shipments are still prospective, the FOX-1P shipments are mentioned but not explicitly tied as the primary new front, and while resources are being invested, the evidence for immediate revenue from the distinct optical/photonics front is not sufficiently concrete to meet all three criteria simultaneously.